論文

国際誌
2022年8月1日

Update on vitamin C administration in critical illness.

Current opinion in critical care
  • Tomoko Fujii
  • ,
  • Yugeesh R Lankadeva
  • ,
  • Rinaldo Bellomo

28
4
開始ページ
374
終了ページ
380
記述言語
英語
掲載種別
研究論文(学術雑誌)
DOI
10.1097/MCC.0000000000000951

PURPOSE OF REVIEW: Several studies have recently explored the effects of intravenous vitamin C in sepsis. We aimed to summarize their findings to provide perspectives for future research. RECENT FINDINGS: Sepsis trials examined 6 g/day of intravenous vitamin C with or without the thiamine and/or hydrocortisone compared with placebo or hydrocortisone. Network meta-analysis reported that intravenous vitamin C, thiamine, hydrocortisone, or combinations of these drugs was not proven to reduce long-term mortality. However, the component network meta-analysis suggested an association of high-dose (>6 g/day) and very-high dose vitamin C (>12 g/day) and decreased mortality but with low certainty. The preclinical investigations have, however, advanced to much higher doses of intravenous vitamin C therapy since a scoping review on harm reported that mega-doses of intravenous vitamin C (50-100 g/day) had been administered without any conclusive adverse effects. In a Gram-negative sheep model, renal tissue hypoperfusion was reversed, followed by improvements in kidney function when a mega-dose of vitamin C (150 g/day equivalent) was administered. SUMMARY: The effect of intravenous vitamin C in critically ill patients has yet to be determined and might be dose-dependent. Clinical studies of very high or mega doses of vitamin C are justified by preclinical data.

リンク情報
DOI
https://doi.org/10.1097/MCC.0000000000000951
PubMed
https://www.ncbi.nlm.nih.gov/pubmed/35797532
ID情報
  • DOI : 10.1097/MCC.0000000000000951
  • PubMed ID : 35797532

エクスポート
BibTeX RIS